Merck & Co., Inc. (MRK)
Merck & Co., Inc. (MRK) is a global healthcare company specializing in pharmaceuticals, vaccines, and biologic therapies. Founded in 1891, it is known for developing innovative medicines across various therapeutic areas including oncology, infectious diseases, cardiology, and immunology. Merck focuses on research and development to improve health outcomes worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 7, 2025 | $0.81 | 2025-09-15 | 2025-09-15 |
| July 8, 2025 | $0.81 | 2025-06-16 | 2025-06-16 |
| April 7, 2025 | $0.81 | 2025-03-17 | 2025-03-17 |
| January 8, 2025 | $0.81 | 2024-12-16 | 2024-12-16 |
| October 7, 2024 | $0.77 | 2024-09-16 | 2024-09-16 |
Dividends Summary
- Merck & Co., Inc. has issued 88 dividend payments over the past 21 years
- The most recent dividend was paid 0 days ago, on October 7, 2025
- The highest dividend payed out to investors during this period was $0.81 per share
- The average dividend paid during this period was $0.50 per share.
Company News
Verona Pharma has been approved for acquisition by MSD for $107 per American Depository Share, with a total transaction value of approximately $10 billion. The High Court of Justice of England and Wales has sanctioned the scheme, with the transaction expected to close on October 7, 2025.
The global viral vector gene therapy market is projected to grow from $13.14 billion in 2024 to $38.39 billion by 2034, driven by advancements in vector design, increasing genetic disease prevalence, and strong R&D investments.
Pharmaceutical stocks rallied after Pfizer reached an agreement with the Trump administration to sell drugs at significant discounts, avoiding potential 100% tariffs. Multiple pharma companies saw substantial stock price increases.
Three Dow stocks offer high dividend yields amid challenging market conditions: Verizon leads with a 6.3% yield, while Chevron and Merck maintain dividend streaks despite revenue and profitability challenges.
Merck's stock has underperformed the industry, sector, and S&P 500 this year due to various challenges, including the upcoming patent expiration of its blockbuster drug Keytruda in 2028 and declining sales of its Gardasil vaccine in China. However, the company has a promising pipeline and new products that could drive long-term growth.
